Once-weekly fluoxetine

Drugs

Volumn 61, Issue 15, 2001, Pages 2221-2228

  Wagstaff, Antona J ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FLUOXETINE; NORFLUOXETINE; PLACEBO;

ANXIETY; APATHY; BACKACHE; CLINICAL TRIAL; DELAYED DRUG RELEASE; DEPRESSION; DISEASE SEVERITY; DOSE CALCULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; HUMAN; INSOMNIA; NAUSEA; NIGHTMARE; PAIN; PATIENT COMPLIANCE; RATING SCALE; RELAPSE; REVIEW; SINUSITIS; SOMNOLENCE; TABLET FORMULATION; THOUGHT DISORDER; VERTIGO;

EID: 0035690055     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161150-00006     Document Type: Review

References (18)

1. Relapse and recurrence of depression: A practical approach for prevention
2. Suboptimal use of antidepressants in the treatment of depression
3. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder
4. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
5. Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness
6. Fluoxetine: A pharmacoeconomic review of its use in depression
7. Long-term nature of depression
8. Fluoxetine: A review of its use in anxiety disorders and mixed anxiety and depression
9. Fluoxetine: A review of its use in women's health
10. Fluoxetine: A review of its therapeutic potential in the treatment of depression associated with physical illness
11. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results of a placebo-controlled, randomized clinical trial
12. Long term treatment outcomes of depression with associated anxiety: Efficacy of a new weekly formulation of fluoxetine
13. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder
14. Sexual functioning during acute and continuation therapy with fluoxetine: A prospective assessment
15. FDA approves Prozac Weekly as first and only medication administered weekly for long-term depression treatment